Financial Updates – Financial Updates

Medline IPO Rockets to ~$40, Raising $6.26B: Valuation Hits $50–$55B

Medline’s IPO raised about $6.3 billion at $2...

The company will use most proceeds to pay dow...

Strong first-day trading and rich valuation m...

The deal’s scale and PE backing could reopen ...

What IASIS Healthcare’s IPO Withdrawal Reveals About Hospital Finance Challenges

Americas M&A Healthcare Services

IASIS Healthcare, a private equity-backed hos...

The company owned 15 acute care hospitals, on...

IASIS withdrew its roughly US$300 million IPO...

In 2017, Steward Health Care acquired IASIS’s...

2025 Biopharma M&A Booms: Patent Cliff Spurs Big Pharma to Secure Late-Stage Assets

Global M&A Healthcare

Biopharma M&A in 2025 shifted to fewer but mu...

Headline acquisitions such as J&J–Intra-Cellu...

Patent cliffs threaten roughly $180–230 billi...

Deal structures feature heavier use of milest...

How 340B, ACA Subsidy Rollbacks & PBM Reform Will Reshape Strategy for Insurers & Health Providers

Americas Policy Healthcare

In 2025, Republicans shifted from defending A...

GOP legislative focus centered on tightening ...

A federal court halted HRSA’s 340B Rebate Mod...

With enhanced ACA subsidies set to lapse at t...

Q3 US Equity Roundup: Dividend Growth Holds While S&P Trails Amid Policy, Inflation Risks

Americas Markets Healthcare

Bristol Gate’s US Equity Strategy posted posi...

The portfolio’s edge remains its focus on hig...

Healthcare holdings like UnitedHealth and The...

Management is tilting further toward resilien...

Feinstein’s Blind Trust Sparks Ethics Questions After Husband’s Allogene Sales near Lows

Americas Policy Biotechnology

In early 2020, Richard Blum, husband of Senat...

The timing of the sales—just before the COVID...

Feinstein says her assets are in a blind trus...

The Justice Department investigated multiple ...

Feinstein-Blum Allegations: Allogene Trades, Blind Trusts & Ethics in Senate

Americas Policy Healthcare

In early 2020, Sen. Dianne Feinstein’s husban...

Feinstein says the assets were in a blind tru...

The FBI questioned Feinstein, but the Justice...

The episode highlights ongoing concerns about...

Feinstein-Blum Allogene Trades: What Reputational Fallout Says About Insider Risk

Americas Risk Healthcare

Sen. Dianne Feinstein’s husband, Richard Blum...

Additional Allogene sales on February 18 brou...

Feinstein says her assets are in a blind trus...

The timing of the trades, amid early coronavi...

EIB’s New Direction: Scaling TechEU, Innovation Finance & Health Autonomy

Europe Tech Healthcare

The European Investment Bank is pivoting from...

Its TechEU programme will deploy €70 billion ...

Recent deals in biotech and digital health (A...

Success hinges on execution quality, attracti...

Feinstein-Blum & Allogene: What We Know — Insider Trading Allegations, Blind Trust Gaps

Americas Risk Healthcare

<div class="section-block section-executivesummary”> Sen. Dianne Feinstein’s husband, Richard Blum, sold $1.5 million to $6 million of Allogene Therapeutics stock between January 31 and February 18, 2020, near the stock’s 2020 lows. The trades occurred just before markets broadly reacted to COVID-19 and before Allogene’s share price rebounded in early March 2020. Feinstein says she had …

Feinstein-Blum & Allogene: What We Know — Insider Trading Allegations, Blind Trust Gaps Read More »